TLX · NASDAQ · Biotechnology

Telix Pharmaceuticals

Commercializes prostate-cancer imaging agents while developing radiopharmaceutical diagnostics and treatments.

$11.29
After-hours close+0.02 (+0.18%)
At close$11.27(−0.92%)
DateEstimateReportedSurprise
Aug 2026$0.04$0.11+140.3%
Feb 2026$0.03−$0.01−135.4%
Aug 2025$0.13−$0.01−105.1%
Feb 2025$0.09$0.07−25.2%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 2024
Dec 2023
Jun 2023
Dec 2022
Jun 2022
Dec 2021
Jun 2021
Dec 2020
Jun 2020
Dec 2019
Jun 2019
Dec 2018
Jun 2018
Dec 2017
Jun 2017
Jan 2017
Dec 2016
Jun 2016
Dec 2015
Jun 2015
Dec 2014
Sep 2014
Jun 2014
Mar 2014
Dec 2013
Sep 2013
Jun 2013
Mar 2013
Dec 2012
Sep 2012
Jun 2012
Mar 2012
Dec 2011
Sep 2011
Jun 2011
Sep 2000
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Aug 19, 2026$0.04$0.11+140.3%$479.6M$477.0M−0.5%
Feb 19, 2026$0.03−$0.01−135.4%$418.5M$413.4M−1.2%
Aug 20, 2025$0.13−$0.01−105.1%$322.9M$388.6M+20.4%
Feb 20, 2025$0.09$0.07−25.2%$135.1M$367.8M+172.3%

The latest year is open to everyone — the 36 quarters behind it read with an account.

Sign in
Aug 22, 2024
Dec 31, 2023
Jun 30, 2023
Dec 31, 2022
Jun 30, 2022
Dec 31, 2021
Jun 30, 2021
Dec 31, 2020
Jun 30, 2020
Dec 31, 2019
Jun 30, 2019
Dec 31, 2018
Jun 30, 2018
Dec 31, 2017
Jun 30, 2017
Jan 31, 2017
Dec 31, 2016
Jun 30, 2016
Dec 31, 2015
Jun 30, 2015
Dec 31, 2014
Sep 30, 2014
Jun 30, 2014
Mar 31, 2014
Dec 31, 2013
Sep 30, 2013
Jun 30, 2013
Mar 31, 2013
Dec 31, 2012
Sep 30, 2012
Jun 30, 2012
Mar 31, 2012
Dec 31, 2011
Sep 30, 2011
Jun 30, 2011
Sep 30, 2000